Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: Results from the nurses' health study

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 5, 2009, Pages 1624-1630

  Hecht, Jonathan L ^a   Kotsopoulos, Joanne ^b,d   Hankinson, Susan E ^b,c   Tworoger, Shelley S ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR;

ADULT; AGE; ARTICLE; BODY MASS; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NURSE; ORAL CONTRACEPTION; OVARY CANCER; PARITY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; ANTHROPOMETRY; CASE-CONTROL STUDIES; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; NEOPLASM STAGING; OVARIAN NEOPLASMS; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 66549108583     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1214     Document Type: Article

References (49)

1. Beral V, Banks E, Reeves G. Effects of estrogen-only treatment in postmenopausal women. JAMA 2004;292:684; author reply 5-6. (Pubitemid 39062521)
2. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-1465 (Pubitemid 32221894)
3. Lacey JV, Jr., Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-341 (Pubitemid 34761612)
4. Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004;15:100-104 (Pubitemid 40417003)
5. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 2007;96:151-156 (Pubitemid 46094654)
6. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002;156:363-373
7. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-1568 (Pubitemid 39331875)
8. Glavind K, Grove A. Estrogen and progesterone receptors in epithelial ovarian tumours. APMIS 1990;98:916-920 (Pubitemid 20371573)
9. Geisler JP, Buller E, Manahan KJ. Estrogen receptor A and B expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. Eur J Gynaecol Oncol 2008;29:126-128
10. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44. (Pubitemid 350218778)
11. Cho EY, Choi YL, Chae SW, Sohn JH, Ahn GH. Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms. Int J Gynecol Cancer 2006;16:1000-1006 (Pubitemid 43886717)
12. Hogdall EV, Christensen L, Hogdall CK, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007;18:1051-1059
13. Colditz GA. The nurses' health study: a cohort of US women followed since 1976. J Am Med Womens Assoc 1995;50:40-44
14. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 1997;6:49-62. (Pubitemid 27132646)
15. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 2005;5:388-396 (Pubitemid 40637830)
16. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol 1984;119:837-839 (Pubitemid 14142821)
17. Hecht JL, Kotsopoulos J, Gates MA, Hankinson SE, Tworoger SS. Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 2008;17:3043-3050
18. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481 (Pubitemid 29220854)
19. Glynn RJ, Rosner B. Methods to evaluate risks for composite end points and their individual components. J Clin Epidemiol 2004;57:113-122 (Pubitemid 38678613)
20. Bertone ER, Willett WC, Rosner BA, et al. Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst 2001;93:942-948 (Pubitemid 32624652)
21. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol 2002;100:288-296
22. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007;166:894-901. (Pubitemid 47511685)
23. Hosmer D, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
24. Vang R, Whitaker BP, Farhood AI, Silva EG, Ro JY, Deavers MT. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001;20:252-259 (Pubitemid 32578111)
25. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005;96:671-677 (Pubitemid 40255486)
26. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006;19:97-105. (Pubitemid 43250984)
27. Harding M, Cowan S, Hole D, et al. Estrogen and progesterone receptors in ovarian cancer. Cancer 1990;65:486-491 (Pubitemid 20058365)
28. Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992;47:317-322 (Pubitemid 23011411)
29. Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000;89:1783-1791
30. Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991;12:14-26.
31. Clinton GM, Hua W. Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 1997;25:1-9. (Pubitemid 27138045)
32. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-1786 (Pubitemid 28559889)
33. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-A and -B, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 1999;96:5722-5727 (Pubitemid 29234685)
34. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-160
35. Schnitt SJ. Benign breast disease and breast cancer risk: potential role for antiestrogens. Clin Cancer Res 2001;7:4419-22s; discussion 1-2s. (Pubitemid 34031590)
36. Fujimura M, Hidaka T, Kataoka K, et al. Absence of estrogen receptor-A expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 2001;25:667-672 (Pubitemid 32423367)
37. Gutgemann I, Lehman NL, Jackson PK, Longacre TA. Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol 2008;21:445-454
38. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997;89:932-938 (Pubitemid 27282065)
39. Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, Chenevix-Trench G. Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1998;90:1729-1734 (Pubitemid 28539093)
40. Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004;94:25-32.
41. Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 2006;12:1013-8s. (Pubitemid 43259837)
42. Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol 1995;55:279-289 (Pubitemid 26022200)
43. Narod SA, Foulkes WD. BRCA1 and BRCA2:1994 and beyond. Nat Rev Cancer 2004;4:665-676
44. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 2002;13:807-811 (Pubitemid 35305199)
45. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005;14:98-107. (Pubitemid 40165289)
46. Schouten LJ, Rivera C, Hunter DJ, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 2008;17:902-912
47. Gunnell D, Okasha M, Smith GD, Oliver SE, Sandhu J, Holly JM. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 2001;23:313-342 (Pubitemid 34074115)
48. Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 2003;10:331-345 (Pubitemid 36758659)
49. Olsen CM, Bain CJ, Jordan SJ, et al. Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2007;16:2321-2330